When reviewing TUE applications, the Independent TUE Committee follow the guidelines published by WADA for TUE validities for common medical conditions as indicated in the table below.


ADHD First application, up to 1 year. Second and subsequent applications, up to 4 years.
Adrenal insufficiency Primary insufficiency, up to 8 years with annual review by an endocrinologist. Secondary insufficiency, a maximum of 12 months.
Anaphylaxis Up to the date of the last administration of the prohibited substance(s).
Androgen deficiency/ male hypogonadism 1 year.
Arterial hypertension 4 years (no annual review). Eligible for retroactive approval.
Asthma 4 years with annual review; new pulmonary function tests every 4 years.
Diabetes mellitus Type 1, 8 years with annual review. Type 2, annual review and HbA1c.
Female to Male (FtM) transsexuals 8 years with annual review.
Growth hormone deficiency(adults) 8 years.
Growth hormone deficiency(adolescents and children) 1 year.
Polycystic ovarian syndrome/unexplained infertility Clomiphene citrate: 2 years. Spironolactone: 8 years with annual review.
Inflammatory bowel disease 4 years with annual review.
Intrinsic sleep disorders 4 years with annual review by a sleep specialist.
IV infusion Normally a single intervention of relatively short duration. Eligible for retroactive approval.
Musculoskeletal conditions Days or weeks.
Post-infectious cough Normally no longer than 2 months.
Renal transplant Glucocorticosteroids:lifelong. EPO:1 year. Diuretics: 4 years with annual review.
Sinusitis/rhinosinusitis 8 weeks.